中药复方护骨胶囊对糖皮质激素诱导骨质疏松大鼠骨密度和骨形态计量学的研究

Effect of Hugu capsule on BMD and histomorphometry in glucocorticoid-induced osteoporotic rats

目的探讨中药复方护骨胶囊(主要由制何首乌、淫羊藿、熟地黄等多味中药加工而成的复方制剂)对糖皮质激素诱导骨质疏松大鼠骨丢失的影响。方法 3月龄SPF级雄性SD大鼠30只,随机平均分为3组:正常对照组(Nrm)、激素组(Met)和中药组(CH)。Met组:皮下注射甲强龙(Met)5mg/kg/d,每周5次;CH组:在Met组基础上给予中药复方护骨胶囊(150 mg/kg/d)灌胃,实验期12w。大鼠右侧股骨和腰椎行骨密度(BMD)测定,右侧胫骨行骨形态计量学分析。结果 Met组腰椎和股骨BMD显著低于Nrm组;CH组腰椎和股骨BMD显著高于Met组。Met组Tb.N、%Tb.Ar、MS/BS、MAR和BFRs显著低于Nrm组,Tb.Sp、ES/BS显著高于Nrm组;中药组Tb.N、%Tb.Ar、MS/BS、MAR和BFRs显著高于Met组,Tb.Sp,ES/BS显著低于Met组。结论中药复方护骨胶囊在提高激素诱导骨质疏松大鼠的骨密度,促进骨形成,降低骨吸收,延缓骨丢失方面有积极作用,对继发性骨质疏松的预防和治疗有一定前景。

Objective To explore the effects of Hugu Capsule （CH） on bone loss in glucocorticoid （GC） -induced osteoporotie rats. Methods Thirty 3-month-old male Sprague-Dawley rats were randomly divided into 3 groups： age-matched normal control group （Nrm） , methylprednisolone group （Met） , and CH group. Rats in Met group were treated with 5 mg/kg/d Met, 5 times per week. Rats in CH group were treated with CH in the presence of Met. The study period was 12 weeks. Bone mineral density （BMD） of the right femur and the lumbar vertebra 5 of all rats were measured. Histomorphometry analysis was performed in the right tibia. Results BMDs of the femur and the lumbar vertebra of rats in the Met group were significantly lower than those in the Nrm group. BMDs of the femur and the lumbar vertebra of rats in the CH group were significantly higher than those in the Met group. Tb. N, %Tb. Ar, MS/BS, MAR, and BFRs of rats in the Met group were significantly lower than those in the Nrm group. Tb. Sp and ES/BS of rats in the Met group were significantly higher than those in the Nrm group. Tb. N, % Tb. Ar, MS/BS, MAR, and BFRs of rats in the CH group were significantly higher than those in the Met group. Tb. Sp and ES/BS of rats in the CH group were significantly lower than those in the Met group. Conclusion CH has protective effect on increasing BMD of osteoporotic rats, promoting bone formation, decreasing bone absorption, and delaying bone loss. CH might be applicable in the prevention and treatment of secondary osteoporosis.